VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons

Jose A. Serpa, Josemon Valayam, Daniel M. Musher, Roger D. Rossen, Liise-anne Pirofski, Maria C. Rodriguez-Barradas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pneumococcal disease continues to cause substantial morbidity and mortality among the elderly. Older adults may have high levels of anticapsular antibody after vaccination, but their antibodies show decreased functional activity. In addition, the protective effect of the pneumococcal polysaccharide vaccine (PPV) seems to cease as early as 3 to 5 years postvaccination. Recently, it was suggested that PPV elicits human antibodies that use predominantly V H3 gene segments and induce a repertoire shift with increased V H3 expression in peripheral B cells. Here we compared V H3-idiotypic antibody responses in middle-aged and elderly subjects receiving PPV as initial immunization or revaccination. We studied pre- and postvaccination sera from 36 (18 vaccine-naïve and 18 previously immunized subjects) middle-aged and 40 (22 vaccine-naïve and 18 previously immunized subjects) elderly adults who received 23-valent PPV. Concentrations of IgGs to four individual serotypes (6B, 14, 19F, and 23F) and of VH3-idiotypic antibodies (detected by the monoclonal antibody D12) to the whole pneumococcal vaccine were determined by enzyme-linked immunosorbent assay (ELISA). PPV elicited significant IgG and VH3-idiotypic antibody responses in middle-aged and elderly subjects, regardless of whether they were vaccine naïve or undergoing revaccination. Age did not influence the magnitude of the antibody responses, as evidenced by similar postvaccination IgG and V H3 antibody levels in both groups, even after stratifying by prior vaccine status. Furthermore, we found similar proportions (around 50%) of elderly and middle-aged subjects experiencing 2-fold increases in VH3 antibody titers after vaccination. Age or repeated immunization does not appear to affect the VH3-idiotypic immunogenicity of PPV among middle-aged and elderly adults.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalClinical and Vaccine Immunology
Volume18
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Immunization
Pneumococcal Vaccines
Antibody Formation
Antibodies
Vaccines
Secondary Immunization
Vaccination
Immunoglobulin G
Immunosorbents
B-Lymphocytes
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
Assays
Morbidity
Genes
Cells
Mortality
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. / Serpa, Jose A.; Valayam, Josemon; Musher, Daniel M.; Rossen, Roger D.; Pirofski, Liise-anne; Rodriguez-Barradas, Maria C.

In: Clinical and Vaccine Immunology, Vol. 18, No. 3, 03.2011, p. 362-366.

Research output: Contribution to journalArticle

Serpa, Jose A. ; Valayam, Josemon ; Musher, Daniel M. ; Rossen, Roger D. ; Pirofski, Liise-anne ; Rodriguez-Barradas, Maria C. / VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons. In: Clinical and Vaccine Immunology. 2011 ; Vol. 18, No. 3. pp. 362-366.
@article{6a7ab1a3c4614570a27f28a5caf9728a,
title = "VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons",
abstract = "Pneumococcal disease continues to cause substantial morbidity and mortality among the elderly. Older adults may have high levels of anticapsular antibody after vaccination, but their antibodies show decreased functional activity. In addition, the protective effect of the pneumococcal polysaccharide vaccine (PPV) seems to cease as early as 3 to 5 years postvaccination. Recently, it was suggested that PPV elicits human antibodies that use predominantly V H3 gene segments and induce a repertoire shift with increased V H3 expression in peripheral B cells. Here we compared V H3-idiotypic antibody responses in middle-aged and elderly subjects receiving PPV as initial immunization or revaccination. We studied pre- and postvaccination sera from 36 (18 vaccine-na{\"i}ve and 18 previously immunized subjects) middle-aged and 40 (22 vaccine-na{\"i}ve and 18 previously immunized subjects) elderly adults who received 23-valent PPV. Concentrations of IgGs to four individual serotypes (6B, 14, 19F, and 23F) and of VH3-idiotypic antibodies (detected by the monoclonal antibody D12) to the whole pneumococcal vaccine were determined by enzyme-linked immunosorbent assay (ELISA). PPV elicited significant IgG and VH3-idiotypic antibody responses in middle-aged and elderly subjects, regardless of whether they were vaccine na{\"i}ve or undergoing revaccination. Age did not influence the magnitude of the antibody responses, as evidenced by similar postvaccination IgG and V H3 antibody levels in both groups, even after stratifying by prior vaccine status. Furthermore, we found similar proportions (around 50{\%}) of elderly and middle-aged subjects experiencing 2-fold increases in VH3 antibody titers after vaccination. Age or repeated immunization does not appear to affect the VH3-idiotypic immunogenicity of PPV among middle-aged and elderly adults.",
author = "Serpa, {Jose A.} and Josemon Valayam and Musher, {Daniel M.} and Rossen, {Roger D.} and Liise-anne Pirofski and Rodriguez-Barradas, {Maria C.}",
year = "2011",
month = "3",
doi = "10.1128/CVI.00408-10",
language = "English (US)",
volume = "18",
pages = "362--366",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - VH3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons

AU - Serpa, Jose A.

AU - Valayam, Josemon

AU - Musher, Daniel M.

AU - Rossen, Roger D.

AU - Pirofski, Liise-anne

AU - Rodriguez-Barradas, Maria C.

PY - 2011/3

Y1 - 2011/3

N2 - Pneumococcal disease continues to cause substantial morbidity and mortality among the elderly. Older adults may have high levels of anticapsular antibody after vaccination, but their antibodies show decreased functional activity. In addition, the protective effect of the pneumococcal polysaccharide vaccine (PPV) seems to cease as early as 3 to 5 years postvaccination. Recently, it was suggested that PPV elicits human antibodies that use predominantly V H3 gene segments and induce a repertoire shift with increased V H3 expression in peripheral B cells. Here we compared V H3-idiotypic antibody responses in middle-aged and elderly subjects receiving PPV as initial immunization or revaccination. We studied pre- and postvaccination sera from 36 (18 vaccine-naïve and 18 previously immunized subjects) middle-aged and 40 (22 vaccine-naïve and 18 previously immunized subjects) elderly adults who received 23-valent PPV. Concentrations of IgGs to four individual serotypes (6B, 14, 19F, and 23F) and of VH3-idiotypic antibodies (detected by the monoclonal antibody D12) to the whole pneumococcal vaccine were determined by enzyme-linked immunosorbent assay (ELISA). PPV elicited significant IgG and VH3-idiotypic antibody responses in middle-aged and elderly subjects, regardless of whether they were vaccine naïve or undergoing revaccination. Age did not influence the magnitude of the antibody responses, as evidenced by similar postvaccination IgG and V H3 antibody levels in both groups, even after stratifying by prior vaccine status. Furthermore, we found similar proportions (around 50%) of elderly and middle-aged subjects experiencing 2-fold increases in VH3 antibody titers after vaccination. Age or repeated immunization does not appear to affect the VH3-idiotypic immunogenicity of PPV among middle-aged and elderly adults.

AB - Pneumococcal disease continues to cause substantial morbidity and mortality among the elderly. Older adults may have high levels of anticapsular antibody after vaccination, but their antibodies show decreased functional activity. In addition, the protective effect of the pneumococcal polysaccharide vaccine (PPV) seems to cease as early as 3 to 5 years postvaccination. Recently, it was suggested that PPV elicits human antibodies that use predominantly V H3 gene segments and induce a repertoire shift with increased V H3 expression in peripheral B cells. Here we compared V H3-idiotypic antibody responses in middle-aged and elderly subjects receiving PPV as initial immunization or revaccination. We studied pre- and postvaccination sera from 36 (18 vaccine-naïve and 18 previously immunized subjects) middle-aged and 40 (22 vaccine-naïve and 18 previously immunized subjects) elderly adults who received 23-valent PPV. Concentrations of IgGs to four individual serotypes (6B, 14, 19F, and 23F) and of VH3-idiotypic antibodies (detected by the monoclonal antibody D12) to the whole pneumococcal vaccine were determined by enzyme-linked immunosorbent assay (ELISA). PPV elicited significant IgG and VH3-idiotypic antibody responses in middle-aged and elderly subjects, regardless of whether they were vaccine naïve or undergoing revaccination. Age did not influence the magnitude of the antibody responses, as evidenced by similar postvaccination IgG and V H3 antibody levels in both groups, even after stratifying by prior vaccine status. Furthermore, we found similar proportions (around 50%) of elderly and middle-aged subjects experiencing 2-fold increases in VH3 antibody titers after vaccination. Age or repeated immunization does not appear to affect the VH3-idiotypic immunogenicity of PPV among middle-aged and elderly adults.

UR - http://www.scopus.com/inward/record.url?scp=79952542637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952542637&partnerID=8YFLogxK

U2 - 10.1128/CVI.00408-10

DO - 10.1128/CVI.00408-10

M3 - Article

VL - 18

SP - 362

EP - 366

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 3

ER -